IL237352A0 - שיטות טיפול באפילפסיה ובסטטוס אפלילפטיקוס - Google Patents

שיטות טיפול באפילפסיה ובסטטוס אפלילפטיקוס

Info

Publication number
IL237352A0
IL237352A0 IL237352A IL23735215A IL237352A0 IL 237352 A0 IL237352 A0 IL 237352A0 IL 237352 A IL237352 A IL 237352A IL 23735215 A IL23735215 A IL 23735215A IL 237352 A0 IL237352 A0 IL 237352A0
Authority
IL
Israel
Prior art keywords
methods
status epilepticus
treating epilepsy
epilepsy
treating
Prior art date
Application number
IL237352A
Other languages
English (en)
Other versions
IL237352B (he
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of IL237352A0 publication Critical patent/IL237352A0/he
Publication of IL237352B publication Critical patent/IL237352B/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Fire-Extinguishing Compositions (AREA)
  • Gasification And Melting Of Waste (AREA)
  • Carbon And Carbon Compounds (AREA)
IL237352A 2012-08-21 2015-02-22 שיטות טיפול באפילפסיה ובסטטוס אפלילפטיקוס IL237352B (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691545P 2012-08-21 2012-08-21
US201361789491P 2013-03-15 2013-03-15
PCT/US2013/056062 WO2014031792A2 (en) 2012-08-21 2013-08-21 Methods of treating epilepsy or tatus epilepticus

Publications (2)

Publication Number Publication Date
IL237352A0 true IL237352A0 (he) 2015-04-30
IL237352B IL237352B (he) 2019-05-30

Family

ID=50148516

Family Applications (5)

Application Number Title Priority Date Filing Date
IL304912A IL304912A (he) 2012-08-21 2013-08-21 שיטות טיפול באפילפסיה ובסטטוס אפלילפטיקוס
IL294306A IL294306B2 (he) 2012-08-21 2013-08-21 שיטות טיפול באפילפסיה ובסטטוס אפלילפטיקוס
IL275725A IL275725B (he) 2012-08-21 2013-08-21 שיטות טיפול באפילפסיה ובסטטוס אפלילפטיקוס
IL237352A IL237352B (he) 2012-08-21 2015-02-22 שיטות טיפול באפילפסיה ובסטטוס אפלילפטיקוס
IL264414A IL264414B (he) 2012-08-21 2019-01-22 שיטות טיפול באפילפסיה ובסטטוס אפלילפטיקוס

Family Applications Before (3)

Application Number Title Priority Date Filing Date
IL304912A IL304912A (he) 2012-08-21 2013-08-21 שיטות טיפול באפילפסיה ובסטטוס אפלילפטיקוס
IL294306A IL294306B2 (he) 2012-08-21 2013-08-21 שיטות טיפול באפילפסיה ובסטטוס אפלילפטיקוס
IL275725A IL275725B (he) 2012-08-21 2013-08-21 שיטות טיפול באפילפסיה ובסטטוס אפלילפטיקוס

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL264414A IL264414B (he) 2012-08-21 2019-01-22 שיטות טיפול באפילפסיה ובסטטוס אפלילפטיקוס

Country Status (27)

Country Link
US (5) US20140057885A1 (he)
EP (2) EP3957309A1 (he)
JP (3) JP6355633B2 (he)
KR (2) KR102121633B1 (he)
CN (2) CN104736159A (he)
AU (4) AU2013305767B2 (he)
BR (2) BR112015003747A2 (he)
CA (1) CA2882708A1 (he)
CY (1) CY1125070T1 (he)
DK (1) DK2887944T3 (he)
ES (1) ES2902684T3 (he)
HR (1) HRP20220005T1 (he)
HU (1) HUE056838T2 (he)
IL (5) IL304912A (he)
LT (1) LT2887944T (he)
MX (1) MX2015002252A (he)
NZ (1) NZ705410A (he)
PH (2) PH12015500482A1 (he)
PL (1) PL2887944T3 (he)
PT (1) PT2887944T (he)
RS (1) RS62761B1 (he)
RU (1) RU2667010C2 (he)
SG (2) SG10201608148TA (he)
SI (1) SI2887944T1 (he)
SM (1) SMT202200006T1 (he)
WO (1) WO2014031792A2 (he)
ZA (1) ZA201501188B (he)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106667918A (zh) 2005-11-28 2017-05-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
US20150018327A1 (en) 2012-01-23 2015-01-15 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
DK2925327T3 (da) 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
LT2986623T (lt) 2013-04-17 2019-02-25 Sage Therapeutics, Inc. 19-nor c3,3-dipakeistieji c21-n-pirazolilo steroidai ir jų panaudojimo būdai
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA40498A (fr) 2014-09-02 2021-05-19 Texas A & M Univ Sys Méthode de traitement de l'intoxication par organophosphates
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
AU2015331749A1 (en) 2014-10-16 2017-05-04 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
HRP20200840T1 (hr) 2014-11-27 2020-11-13 Sage Therapeutics, Inc. Pripravci i postupci za liječenje poremećaja cns-a
EP3229790B1 (en) 2014-12-08 2019-10-16 Société des Produits Nestlé S.A. Compositions comprising medium chain triglycerides for use in the treatment of epilepsy
US10668041B2 (en) 2014-12-08 2020-06-02 Societe Des Produits Nestle Sa Compositions and methods comprising medium chain triglycerides for treatment of epilepsy
EP3253418A1 (en) * 2015-02-06 2017-12-13 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
BR112017017608A2 (en) 2015-02-17 2018-05-08 Vanda Pharmaceuticals Inc. methods for treating schizophrenia or a symptom of schizophrenia, to prevent a schizophrenic relapse and to maintain the effect of iloperidone for schizophrenia.
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
AU2016338672A1 (en) 2015-10-16 2018-04-12 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
EP3426257A4 (en) * 2016-03-08 2019-11-13 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF
WO2018013615A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
AU2017297375B2 (en) 2016-07-11 2022-09-15 Sage Therapeutics, Inc. C17, C20, and C21 substituted neuroactive steroids and their methods of use
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
TWI854445B (zh) 2016-08-23 2024-09-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
US20200276209A1 (en) * 2017-09-11 2020-09-03 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
WO2019075362A1 (en) 2017-10-12 2019-04-18 Sage Therapeutics, Inc. METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS
CA3079259A1 (en) * 2017-11-10 2019-05-16 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disorders
WO2019113494A1 (en) 2017-12-08 2019-06-13 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
US11446262B2 (en) 2018-11-29 2022-09-20 Debora Zucco Sassi Yonezawa Siviglia Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination
BR112021010336A2 (pt) * 2018-11-29 2021-08-24 Debora Zucco Sassi Yonezawa Siviglia Método para tratar ou prevenir convulsões associadas a um distúrbio epiléptico
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
WO2021026124A1 (en) 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
WO2021113834A1 (en) 2019-12-06 2021-06-10 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
CN113368084A (zh) * 2020-03-10 2021-09-10 上海喀露蓝科技有限公司 含有大麻二酚，丙泊酚前药和别孕烯醇酮前药化合物的药物组合物及其在医药上的应用
CA3176854A1 (en) 2020-03-25 2021-09-30 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
KR20230018462A (ko) * 2020-05-29 2023-02-07 세레신 인코포레이티드 중쇄 트리글리세리드(triglyceride)를 사용한 영아 연축(infantile spasm)의 치료 방법
CN113925832B (zh) * 2020-07-13 2023-06-16 苏州特瑞药业股份有限公司 一种别孕烯醇酮的脂质体及其制备方法
WO2022109440A1 (en) * 2020-11-23 2022-05-27 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of super refractory status epilepticus
WO2023060020A1 (en) * 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of established status epilepticus
TWI804037B (zh) * 2021-11-02 2023-06-01 長庚醫療財團法人高雄長庚紀念醫院 生酮飲食之評估系統及其運作方法

Family Cites Families (198)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3117142A (en) 1961-03-01 1964-01-07 Roussel Uclaf Novel preparation of estradiol and estrone
US3169134A (en) 1963-03-21 1965-02-09 Searle & Co 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
BE754111A (fr) 1969-07-29 1971-01-29 Upjohn Co Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
US3943124A (en) 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
US3983111A (en) 1972-05-05 1976-09-28 Glaxo Laboratories Limited Steroidal anaesthetics of the pregnane and 19-norpregnane series
GB1430942A (en) 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
US3865939A (en) 1973-02-23 1975-02-11 Procter & Gamble Edible oils having hypocholesterolemic properties
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
US4192871A (en) 1976-01-06 1980-03-11 Glaxo Laboratories Limited Chemical compounds
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
US5847009A (en) 1986-01-14 1998-12-08 Alliance Pharmaceutical Corp. Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions
SE8600632D0 (sv) 1986-02-13 1986-02-13 Kabivitrum Ab Novel pharmaceutical composition
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JPH06510999A (ja) 1991-09-13 1994-12-08 コセンシス・インコーポレイテッド ステロイド結合部位を有する新規ＧＡＢＡ↓ａレセプター
AU698834B2 (en) 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
EP0656365B1 (en) 1993-12-02 1997-04-09 Akzo Nobel N.V. Substituted 2beta-morpholinoandrostane derivatives
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
DK1038880T3 (da) 1994-02-14 2008-03-03 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
JP3696884B2 (ja) 1994-03-25 2005-09-21 アイソテクニカ、インコーポレーテッド ジュウテリウム化による薬物の効能の増強
AU3125695A (en) 1994-07-21 1996-02-22 Pharmacia & Upjohn Company Neurologically active aminosteroids
AP653A (en) 1994-11-23 1998-07-21 Cocensys Inc Androstane and pregnane series for allosteric modulations of gaba receptor.
BR9608592A (pt) 1995-06-06 1999-06-29 Cocensys Inc Esteróides neuroativos da série do androstano e do pregnano
US6780853B1 (en) * 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
JP4313435B2 (ja) 1995-07-24 2009-08-12 トラスティーズ オブ ボストン ユニバーシティー プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制
WO1998005337A1 (en) 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
US7630757B2 (en) * 1997-01-06 2009-12-08 Flint Hills Scientific Llc System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6316613B1 (en) 1997-07-25 2001-11-13 Beckman Coulter, Inc. Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis
US6245757B1 (en) 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
CN1270718C (zh) 1998-03-11 2006-08-23 托布乔恩·贝克斯托罗姆 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用
US20020198174A1 (en) 2001-05-07 2002-12-26 Allergan Sales, Inc. Disinfecting and solubilizing steroid compositions
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
ES2193921T3 (es) 1999-12-03 2003-11-16 Pfizer Prod Inc Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.
US6442887B2 (en) 2000-02-25 2002-09-03 Robert L. Sanquist Live bait keeper
IN187686B (he) 2000-06-21 2002-06-08 Bharat Serums & Vaccines Ltd
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US20020072509A1 (en) 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
GR1003861B (el) * 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
AU2002250064B2 (en) 2001-02-13 2008-01-17 University Of Florida Research Foundation, Inc. A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
WO2002094218A2 (en) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US20030032638A1 (en) 2001-05-24 2003-02-13 Kim John J. Delivery of benzodiazepines through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
JP2003063965A (ja) 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
JP2005519294A (ja) 2002-01-14 2005-06-30 アンセル・ヘルスケア・プロダクツ・インコーポレーテッド 磁気検出可能ラテックス物品
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
JP2006506445A (ja) 2002-08-28 2006-02-23 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 治療処置の方法
US9339508B2 (en) 2003-01-17 2016-05-17 Mapreg Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury
EP1626980A4 (en) 2003-05-29 2007-07-04 Univ Washington NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURELY RELATED PENTACYCLIC STEROIDS
WO2005011612A2 (en) * 2003-07-31 2005-02-10 The Research Foundation Of State University Of New York Alpha 4 beta 2 delta gaba-a receptors as a strategy for pms and alcoholism
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
DE602005026225D1 (de) 2004-03-12 2011-03-24 Cipla Ltd Sterilisationsprozess für Steroide
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
ITMI20041763A1 (it) 2004-09-16 2004-12-16 Altergon Sa Nuove formulazioni iniettabili contenenti progesterone
US20060063707A1 (en) 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
WO2006037016A2 (en) 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
US8557861B2 (en) 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
EP1807118B8 (en) 2004-09-29 2014-04-23 Harbor Therapeutics, Inc. Steroid analogs and characterization and treatment methods
WO2006088894A2 (en) 2005-02-15 2006-08-24 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
PL2030622T3 (pl) 2005-03-24 2011-07-29 Univ Emory Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu
US20080207601A1 (en) * 2005-04-07 2008-08-28 Hythiam , Inc. Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence
US20110319386A1 (en) 2005-08-26 2011-12-29 Braincells Inc. Neurogenesis by muscarinic receptor modulation
CN106667918A (zh) 2005-11-28 2017-05-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
EP1996556B1 (en) * 2005-12-05 2009-11-18 NeuroSearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
US20070287931A1 (en) 2006-02-14 2007-12-13 Dilorenzo Daniel J Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
US20090074677A1 (en) 2007-01-08 2009-03-19 Duke University Neuroactive steroid compositions and methods of use therefor
US20090203658A1 (en) 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
US7813811B2 (en) 2007-02-08 2010-10-12 Neuropace, Inc. Refillable reservoir lead systems
HRP20220188T3 (hr) 2007-04-11 2022-04-29 Biomarin Pharmaceutical Inc. Načini primjene tetrahidrobiopterina, povezani pripravci i postupci mjerenja
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
EP2167098B1 (en) 2007-06-11 2018-09-05 University Of Southern California Allopregnanolone in a method for enhancing neurological function (alzheimer disease)
US8575375B2 (en) 2007-06-15 2013-11-05 Research Triangle Institute Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
EP2173169B1 (en) * 2007-06-28 2014-05-21 CyDex Pharmaceuticals, Inc. Nasal delivery of aqueous corticosteroid solutions
US20100316678A1 (en) 2007-06-28 2010-12-16 Cnsbio Pty Ltd. Combination methods and compositions for treatment of neuropathic pain
US20100297181A1 (en) 2007-12-26 2010-11-25 Eisai R&D Management Co., Ltd. AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
WO2009088530A1 (en) 2008-01-03 2009-07-16 Biomarin Pharmaceutical Inc. Pterin analog for treating bh4 responsive condition
US20090198145A1 (en) 2008-02-06 2009-08-06 Chow Harrison Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
US8729070B2 (en) 2008-02-20 2014-05-20 Targia Pharmaceuticals CNS pharmaceutical compositions and methods of use
DE102008015366A1 (de) 2008-03-20 2009-09-24 Merck Patent Gmbh Lyophilisierte Nanoemulsion
CZ301216B6 (cs) 2008-07-10 2009-12-09 Ústav organické chemie a biochemie Akademie ved CR, v. v. i. Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
ES2438496T3 (es) * 2008-08-01 2014-01-17 Ventirx Pharmaceuticals, Inc. Formulaciones de agonistas de receptores de tipo toll y su uso
SMT201700147T1 (it) * 2008-10-10 2017-05-08 Vm Discovery Inc Composizioni e metodi per il trattamento dei disturbi da uso di alcol, dolore e altre malattie
EP2376073A2 (en) * 2008-11-30 2011-10-19 Oron Zachar Dermal application of vasoconstrictors
US20110306579A1 (en) * 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
WO2010107922A1 (en) 2009-03-17 2010-09-23 Duke University Neuroactive steroid compositions and methods of use for lowering cholesterol
WO2011079047A1 (en) 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
SMT201700518T1 (it) * 2010-01-21 2018-01-11 Drawbridge Pharmaceuticals Pty Ltd Formulazione anestetica
CA2816806A1 (en) * 2010-11-03 2012-05-10 Sanofi-Aventis Deutschland Gmbh Needle cannula containing medicament
US20130309306A1 (en) 2010-12-01 2013-11-21 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
CZ303443B6 (cs) 2011-02-15 2012-09-12 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
WO2012116290A2 (en) 2011-02-25 2012-08-30 Washington University Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
FR2973031B1 (fr) 2011-03-23 2013-11-29 Univ Strasbourg Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
US9084797B2 (en) 2011-05-23 2015-07-21 Besins Healthcare Luxembourg Sarl Progesterone treatment for improving sleep quality
US9526718B2 (en) 2011-06-28 2016-12-27 Vivozon, Inc. Combination of effective substances causing synergistic effects of multiple targeting and use thereof
WO2013019711A2 (en) 2011-07-29 2013-02-07 The Regents Of The University Of California NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
RS64332B1 (sr) 2011-09-08 2023-08-31 Sage Therapeutics Inc Neuroaktivni steroidi, kompozicije i njihova upotreba
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
CN119192266A (zh) 2011-10-14 2024-12-27 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
EP2785354B1 (en) 2011-11-29 2020-09-09 Amino Up Chemical Co., Ltd. Composition comprising vicenin-2 having a beneficial effect on neurological and/or cognitive function
US20150018327A1 (en) 2012-01-23 2015-01-15 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders
WO2013188792A2 (en) 2012-06-15 2013-12-19 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
WO2014058736A1 (en) 2012-10-08 2014-04-17 Washington University Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
US9757391B2 (en) 2012-11-09 2017-09-12 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
DK2925327T3 (da) 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
LT2935307T (lt) 2012-12-18 2018-07-25 Washington University Neuroaktyvūs 19-alkoksi-17-pakeistieji steroidai, tinkami panaudoti gydymo būduose
WO2014108808A2 (en) 2013-01-09 2014-07-17 Henry James Lorne Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
LT2986623T (lt) 2013-04-17 2019-02-25 Sage Therapeutics, Inc. 19-nor c3,3-dipakeistieji c21-n-pirazolilo steroidai ir jų panaudojimo būdai
LT2986624T (lt) 2013-04-17 2020-07-10 Sage Therapeutics, Inc. Neuroaktyvūs 9-nor steroidai, skirti gydymo metodams
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
RS61733B1 (sr) 2013-07-19 2021-05-31 Sage Therapeutics Inc Neuroaktivni steroidi, njihove kompozicije i upotrebe
BR112016003862B1 (pt) 2013-08-23 2022-09-06 Sage Therapeutics, Inc Compostos esteroides neuroativos, suas composições e seus usos
IL292461B2 (he) 2014-05-29 2024-03-01 Sage Therapeutics Inc 3?–הידרוקסי–3?–מתוקסימתיל–21–(5–מתיל–2h– טטראזול–2–יל)–19–נור–5?–פרגננ–20–ון לשימוש בשיטה לטיפול באי–סדרים הקשורים למערכת העצבים המרכזית
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP3753927B1 (en) 2014-10-16 2023-07-19 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
AU2015331749A1 (en) 2014-10-16 2017-05-04 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
HRP20200840T1 (hr) 2014-11-27 2020-11-13 Sage Therapeutics, Inc. Pripravci i postupci za liječenje poremećaja cns-a
LT3250210T (lt) 2015-01-26 2021-04-12 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti gydyti cns sutrikimus
EP3253418A1 (en) 2015-02-06 2017-12-13 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
WO2016164763A1 (en) 2015-04-10 2016-10-13 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
GB2541015A (en) 2015-08-06 2017-02-08 Ge Oil & Gas Uk Ltd Subsea flying lead
EP3362069A4 (en) 2015-10-14 2019-10-02 The Regents of The University of California INCREASING BETA CELL REPLICATION AND / OR SURVIVAL
MA43284A (fr) 2015-11-20 2018-09-26 Sage Therapeutics Inc Composés et leurs méthodes d'utilisation
EP3426257A4 (en) 2016-03-08 2019-11-13 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF
WO2018013615A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
AU2017297375B2 (en) 2016-07-11 2022-09-15 Sage Therapeutics, Inc. C17, C20, and C21 substituted neuroactive steroids and their methods of use
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
US20180050107A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Neurosteroid compositions and methods of use thereof
US20180050005A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
TWI854445B (zh) 2016-08-23 2024-09-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
IL265225B (he) 2016-09-07 2022-08-01 Glia Llc טיפול בסימפטומים הקשורים להפרעות נוירודגנרטיביות באמצעות אקטיבציה דרמית פרמקולוגית של עצבים גולגולתים
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2018169798A1 (en) 2017-03-11 2018-09-20 The Regents Of The University Of California Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers
US20180296487A1 (en) 2017-04-18 2018-10-18 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US11752115B2 (en) 2017-06-21 2023-09-12 The Board Of Trustees Of The University Of Illinois PPAR-alpha agonist treatment of neuropsychiatric disorders
JP7557185B2 (ja) 2017-06-23 2024-09-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫応答を調節するｇａｂａの能力の強化
US11266663B2 (en) 2017-06-23 2022-03-08 The Board Of Trustees Of The University Of Illinois Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
MX2020002652A (es) 2017-09-07 2020-09-25 Sage Therapeutics Inc Esteroides neuroactivos y su método de uso.
US20200276209A1 (en) 2017-09-11 2020-09-03 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
TW202339764A (zh) 2017-09-14 2023-10-16 美商賽吉醫療公司 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法
CA3079259A1 (en) 2017-11-10 2019-05-16 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disorders
WO2019113494A1 (en) 2017-12-08 2019-06-13 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
WO2019126761A1 (en) 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US20210101928A1 (en) 2017-12-22 2021-04-08 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US11718642B2 (en) 2018-01-12 2023-08-08 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
AR116659A1 (es) 2018-05-04 2021-06-02 Acerus Pharmaceuticals Corp Derivados de neuroesteroides y usos de estos
JP2021527092A (ja) 2018-06-12 2021-10-11 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
MX2021004159A (es) 2018-10-12 2021-09-08 Sage Therapeutics Inc Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para uso en el tratamiento de trastornos del snc.
AU2019359899B2 (en) 2018-10-19 2024-07-04 Sage Therapeutics, Inc. 9(11)-unsaturated neuroactive steroids and their methods of use
JP2022506944A (ja) 2018-11-08 2022-01-17 ヴァーソナ セラピューティクス，インコーポレーテッド ５－α－レダクターゼ阻害剤の局所製剤及びそれらの使用
MX2021005992A (es) 2018-11-21 2021-09-14 Certego Therapeutics Inc Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
EP3902818A1 (en) 2018-12-05 2021-11-03 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
AU2019396139A1 (en) 2018-12-14 2021-07-15 Acerus Biopharma Inc. Active ester derivatives of testosterone, compositions and uses thereof
TWI892697B (zh) 2018-12-21 2025-08-01 美商賽吉醫療公司 神經活性類固醇及其組合物
TWI855081B (zh) 2019-05-24 2024-09-11 美商賽吉醫療公司 化合物、組合物及使用方法
WO2020243488A1 (en) 2019-05-31 2020-12-03 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
EP3990468A1 (en) 2019-06-27 2022-05-04 Sage Therapeutics, Inc. Compounds for treating cns disorders
AU2020302748A1 (en) 2019-06-27 2022-01-06 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
WO2020264495A1 (en) 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
IL293510A (he) 2019-12-05 2022-08-01 Sage Therapeutics Inc סטרואיד 19-nor c3,3 -דימותמר c21-n-פיראזוליל ושיטות לשימוש בו
IL296371A (he) 2020-03-18 2022-11-01 Sage Therapeutics Inc סטרואידים פעילים עצבית ושיטות לשימוש בהם
CA3176854A1 (en) 2020-03-25 2021-09-30 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
MX2022016343A (es) 2020-06-24 2023-03-06 Sage Therapeutics Inc Esteroides neuroactivos y composiciones de estos.
BR112023000990A2 (pt) 2020-07-20 2023-03-28 Sage Therapeutics Inc Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas
JP2023550653A (ja) 2020-11-25 2023-12-04 セージ セラピューティクス， インコーポレイテッド Ｃｎｓの障害を治療するための組成物及び方法
IL304080A (he) 2021-01-28 2023-08-01 Sage Therapeutics Inc שימוש בסטרואידים נוירואקטיביים לטיפול בתפקוד מיני לקוי
WO2022177718A1 (en) 2021-02-18 2022-08-25 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
TW202300156A (zh) 2021-03-17 2023-01-01 美商賽吉醫療公司 用於治療重度憂鬱症之19-nor-c3,3-二取代c21-n-吡唑基類固醇
BR112023021131A2 (pt) 2021-04-12 2023-12-19 Sage Therapeutics Inc Tratamento de tremor essencial
WO2022232494A1 (en) 2021-04-29 2022-11-03 Sage Therapeutics, Inc. Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female
CA3218072A1 (en) 2021-04-29 2022-11-03 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
WO2023158668A1 (en) 2022-02-16 2023-08-24 Sage Therapeutics, Inc. Neuroactive steroids for treatment of cns-related disorders
US20250177418A1 (en) 2022-02-28 2025-06-05 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions

Also Published As

Publication number Publication date
RU2015109956A (ru) 2016-10-20
SG10201608148TA (en) 2016-11-29
CA2882708A1 (en) 2014-02-27
KR20200067922A (ko) 2020-06-12
PT2887944T (pt) 2022-01-10
WO2014031792A2 (en) 2014-02-27
US12048706B2 (en) 2024-07-30
AU2020204359A1 (en) 2020-07-23
US20190038639A1 (en) 2019-02-07
RS62761B1 (sr) 2022-01-31
KR102121633B1 (ko) 2020-06-10
IL264414A (he) 2019-02-28
KR102305359B1 (ko) 2021-09-24
US20220152050A1 (en) 2022-05-19
BR112015003747A2 (pt) 2017-07-04
RU2667010C2 (ru) 2018-09-13
JP2021059608A (ja) 2021-04-15
JP6355633B2 (ja) 2018-07-11
AU2018220028A1 (en) 2018-09-06
CN104736159A (zh) 2015-06-24
AU2013305767B2 (en) 2018-05-24
RU2018132041A3 (he) 2022-03-31
AU2022202277A1 (en) 2022-04-21
ZA201501188B (en) 2016-09-28
IL237352B (he) 2019-05-30
JP2015527371A (ja) 2015-09-17
KR20150054846A (ko) 2015-05-20
DK2887944T3 (da) 2022-01-03
WO2014031792A3 (en) 2014-04-10
EP3957309A1 (en) 2022-02-23
JP2018154652A (ja) 2018-10-04
ES2902684T3 (es) 2022-03-29
PH12015500482A1 (en) 2015-04-20
NZ705410A (en) 2018-03-23
IL294306B2 (he) 2024-01-01
HRP20220005T1 (hr) 2022-04-01
AU2013305767A1 (en) 2015-03-19
MX2015002252A (es) 2015-07-21
US20250161325A1 (en) 2025-05-22
IL294306A (he) 2022-08-01
IL264414B (he) 2020-07-30
IL294306B1 (he) 2023-09-01
SI2887944T1 (sl) 2022-02-28
CY1125070T1 (el) 2023-06-09
IL275725B (he) 2022-08-01
IL275725A (he) 2020-08-31
HUE056838T2 (hu) 2022-04-28
AU2018220028B2 (en) 2020-04-02
IL304912A (he) 2023-10-01
PL2887944T3 (pl) 2022-02-21
BR122021022560B1 (pt) 2022-08-09
PH12020500065A1 (en) 2021-04-26
EP2887944A2 (en) 2015-07-01
SMT202200006T1 (it) 2022-03-21
EP2887944B1 (en) 2021-10-06
EP2887944A4 (en) 2016-02-10
LT2887944T (lt) 2022-01-10
JP6829224B2 (ja) 2021-02-10
US20190269699A1 (en) 2019-09-05
SG11201501911RA (en) 2015-04-29
CN111529537A (zh) 2020-08-14
US20140057885A1 (en) 2014-02-27
HK1209025A1 (en) 2016-03-24
RU2018132041A (ru) 2018-11-13

Similar Documents

Publication Publication Date Title
IL294306A (he) שיטות טיפול באפילפסיה ובסטטוס אפלילפטיקוס
IL288181A (he) שיטות לטיפול בסרטן
GB2513074B (en) Treated apertures
ZA201500152B (en) Methods of treating arthritis
EP2879689A4 (en) METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS
LT2857019T (lt) Išsėtinės sklerozės gydymo būdas
IL260115A (he) שיטות לטיפול בפיברוזיס (לייפת)
IL237449A0 (he) שיטות לטיפול במצבים בריאותיים הקשורים לשיער
PT2811993T (pt) Métodos de tratamento da fibrose
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201221032D0 (en) Method of treatment
GB201207894D0 (en) Method of treatment

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed